Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News

ecancer sources relevant oncology news from key institutes, journals, governments, NGOs and charities, along with commissioned pieces from our dedicated news team.

For the latest ecancer COVID-19 resources, click on this link

ASCO 2023: Nivolumab reduces risk of disease progression or death in untreated hodgkin lymphoma compared to brentuximab

ASCO 2023: Nivolumab reduces risk of disease progression or death in untreated hodgkin lymphoma compared to...

ASCO 2023: Radiation can be safely omitted in select patients with locally advanced rectal cancer

ASCO 2023: Radiation can be safely omitted in select patients with locally advanced rectal cancer

ASCO 2023: Real-world data suggests stopping immunotherapy after two years is reasonable in patients with advanced lung cancer

ASCO 2023: Real-world data suggests stopping immunotherapy after two years is reasonable in patients with advanced...

ASCO 2023: Phase 3 trial demonstrates one-year progression-free survival in 94% of patients with stage 3 or 4 classic Hodgkin lymphoma who received a checkpoint inhibitor combined with chemotherapy

ASCO 2023: Phase 3 trial demonstrates one-year progression-free survival in 94% of patients with stage 3 or 4...

ASCO 2023: Study may provide clues to treating colorectal cancer more effectively in younger patients

ASCO 2023: Study may provide clues to treating colorectal cancer more effectively in younger patients

ASCO 2023: Global study finds simple hysterectomy a safe option for people with early-stage, low-risk cervical cancer

ASCO 2023: Global study finds simple hysterectomy a safe option for people with early-stage, low-risk cervical...

ASCO 2023: Adding ribociclib to hormonal therapy reduces risk of recurrence for people with most common subtype of breast cancer

ASCO 2023: Adding ribociclib to hormonal therapy reduces risk of recurrence for people with most common subtype of...

ASCO 2023: For advanced, HER2-amplified bile duct cancers, antibody treatment trial shows promising results

ASCO 2023: For advanced, HER2-amplified bile duct cancers, antibody treatment trial shows promising results

ASCO 2023: Addition of olaparib and durvalumab prolonged progression-free survival in patients with advanced ovarian cancer

ASCO 2023: Addition of olaparib and durvalumab prolonged progression-free survival in patients with advanced...

Memory killer cells can improve survival for melanoma patients

Memory killer cells can improve survival for melanoma patients

Tweets by @ecancer

More from ecancer